LeafNLP Demos
Back to explore

Report #2888679

Received Mar 12, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
—
Recovered
Recovered
Vaccinated
Mar 6, 2026
Onset
Mar 7, 2026
Days to onset
1
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2UNK—

Symptoms (3)

ChillsHeadacheMyalgia

Symptom narrative

Headache; Chills; Myalgia; This non-serious case was reported by a consumer and described the occurrence of headache in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included hyperlipidemia. Concomitant products included rosuvastatin calcium (Crestor). On 06-MAR-2026, the patient received the 2nd dose of Shingrix. On 07-MAR-2026, 1 days after receiving Shingrix, the patient experienced headache (Verbatim: Headache), chills (Verbatim: Chills) and myalgia (Verbatim: Myalgia). On 07-MAR-2026, the outcome of the headache, chills and myalgia were resolved. It was unknown if the reporter considered the headache, chills and myalgia to be related to Shingrix. It was unknown if the company considered the headache, chills and myalgia to be related to Shingrix. Additional Information: GSK Receipt Date: 08-MAR-2026 The batch number was not provided, and we are unable to contact the reporter.

Current illness

Hyperlipidemia

Other medications

CRESTOR